10 Future trials should be larger and placebo-controlled, and they should use a standardized dose and outcome measures. The Lumacaftor mw present study is the first pilot study to compare the therapeutic effects between IVVP (Orifil) and IV Dexamethasone (IVDEX) in patients

with migraine status. Methods This prospective, controlled clinical trial recruited patients from our Emergency Division and Headache Clinic during 2011. Randomization was performed by a computerized software package. Neurologist and patient were blind to the selected therapeutic approach for each patient. Blinding was done by a research fellow. Diagnosis of migraine status was made by a neurologist Inhibitors,research,lifescience,medical according to the second edition of the International Headache Society (IHS) criteria,11 whereby migraine status was defined as a debilitating severe migraine attack lasting for more than 72 hours, and a present attack was that not attributable to another disorder. Interruption of headache during sleep and short lasting relief Inhibitors,research,lifescience,medical due to medication is disregarded disorder.11 Patients aged less than 18 years, pregnant women, and patients with liver failure were excluded.12 Patients with dementia, aphasia, and psychiatric disorders were also

Inhibitors,research,lifescience,medical excluded. The severity of pain was classified based on the Pain Intensity Instrument, using a 0-to-10 point numeric rating scale.13 The patient was asked about what number on the 0-to-10 scale he/she would give for pain before treatment.12,13 Patients with migraine status were randomized into two therapeutic groups. An IV line was then established. In the first group, 16 mg IVDEX was diluted in 150 cc normal saline and infused for 10 minutes. (Patients at a minimum weight Inhibitors,research,lifescience,medical of 90 kg received 20 mg IVDEX.) The second group received 900 mg IVVP (Orifil) diluted in 150 cc normal saline and infused for 10 minutes. (Patients at a minimum weight of 90 kg received 1200 mg IVVP.) The patients were thereafter asked to rate the severity of their headache when it had

the highest relief over a 3-hour period following the infusion.12 Inhibitors,research,lifescience,medical IVDEX has been the routine management of migraine status in our hospital in the recent decade. This standard of care in our hospital PAK6 was fully explained to the patients; and if they agreed to receive IVVP, they were recruited in the case group. The worst severity of pain before treatment and the least severity over a 3-hour period after the infusion were recorded. The time to maximum relief and the time to onset of relief were recorded as well.12 Additionally, mean age, mean history of migraine, mean number of attacks per month, presence of aura, full recovery of headache post treatment, and recovery from nausea and photophobia post treatment were recorded in the questionnaire. Full recovery from headache post treatment was defined as pain-free response.